Medical Properties Trust, Inc. – Consensus ‘buy’ rating and 48.6% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Medical Properties Trust, Inc. which can be found using ticker (MPW) now have 13 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 18 and 8 with the average target price sitting at $11.62. Given that the stocks previous close was at $7.82 this would imply there is now a potential upside of 48.6%. The 50 day moving average now sits at $8.09 and the 200 moving average now moves to $11.39. The market cap for the company is 4.73B. The stock price is currently at: 7.9 USD

The potential market cap would be $7,023,369,458 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 15.8, revenue per share of 2.55 and a 3.14% return on assets.

Medical Properties Trust, Inc. is a real estate investment trust (REIT), which is engaged in the business of investing in, owning, and leasing healthcare real estate. The Company conducts all of its operations through its subsidiary, MPT Operating Partnership, L.P. (the Operating Partnership). The Company acquires and develops healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases. It also makes mortgage loans to healthcare operators collateralized by their real estate assets. In addition, the Company selectively make loans to certain of its operators through its taxable REIT subsidiaries (TRS). The Company have healthcare investments in the United States, Europe, Australia, and South America. The Company’s portfolio (including real estate assets in joint ventures) consists of approximately 444 properties leased or loaned to 55 operators, of which seven are under development and five are in the form of mortgage loans.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search